Clinical Trial Update: Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics study of apixaban in end-stage kidney disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: ESRD, Anticoagulant Toxicity | Phase 2 | Status: COMPLETED